Mizuho lowered the firm’s price target on Adaptimmune (ADAP) to $1.50 from $3 and keeps an Outperform rating on the shares. The firm updated the company’s model post the Q3 results. The analyst says the quarter brought a “mix of good news and bad.”
Mizuho lowered the firm’s price target on Adaptimmune (ADAP) to $1.50 from $3 and keeps an Outperform rating on the shares. The firm updated the company’s model post the Q3 results. The analyst says the quarter brought a “mix of good news and bad.”
